Find disease awareness content and relevant supporting materials

Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway.

Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM).

Phase I part:� - To assess the MTD and the dose-limiting toxicities (DLTs).� Phase II part: - To assess the objective response rate...

This update covers recommendations for glioblastoma; anaplastic astrocytoma, oligoastrocytoma and oligodendroglioma; and diffuse glioma. The recommendations cover clinically relevant problems in: diagnosis and pathology...

The REDUC ("Kick and Kill") trial's objective is to address one of the core issues with the treatment of HIV,...

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center...

With the release of the 2016 edition of the WHO Classification of Central Nervous System Tumors, brain invasion in meningiomas has been added as a stand-alone criterion for atypia and can therefore impact grading and indirectly adjuvant therapy.

The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors).

A decrease of >0.5 log10 from baseline to week 16 in the size of the latent HIV-reservoir as measured by...

Spectrum Pharmaceuticals announced that the that the company has submitted a New Drug Application (NDA) to the FDA for approval...